Table 1. overview of the clinical information of TCGA cohort.
| A | |||
|---|---|---|---|
| Parameter | Histological grade 1 (HG1) | Histological grade 2 (HG2) | Histological grade 3 (HG3) |
| number of samples | 32 | 183 | 215 |
| ER+/ER−/NA | 31/0/1 | 163/17/3 | 127/85/3 |
| PGR+/PGR−/NA | 29/2/1 | 145/35/3 | 100/111/4 |
| HER2+/HER2−/ Her2(eq)/NA | 1/21/7/3 | 22/154/4/3 | 46/108/29/32 |
| Age median (SD) | 59 (13.2) | 60 (13.8) | 56 (12.6) |
| stage I/II/III/IV/X/NA | 9/20/2/1/0/0 | 37/99/34/6/5/2 | 27/124/52/6/6/0 |
| LN+/LN−/NA | 11/21/0 | 93/90/0 | 115/99/1 |
| M+/M−/NA | 1/31/0 | 5/177/1 | 6/205/4 |
| B | |||
|---|---|---|---|
| Parameter | Genetic Grade 1-like (HG1-like) | Genetic Grade 3-like (HG3-like) | Genetic Grade 2 (GG2) |
| number of samples | 101 | 78 | 4 |
| ER+/ER−/NA | 96/5/0 | 63/12/3 | 4/0/0 |
| PGR+/PGR−/NA | 89/12/0 | 53/22/3 | 3/1/0 |
| HER2+/HER2−/ Her2(eq)/NA | 6/92/2/1 | 15/59/2/2 | 1/3/0 |
| Age median (SD) | 61 (13.6) | 58 (14) | 53.5 (17) |
| stage I/II/III/IV/X/NA | 25/52/18/2/2/2 | 12/46/14/4/2/0 | 0/1/2/0/1/0 |
| LN+/LN- | 53/48 | 37/41 | 3/1 |
| M+/M−/NA | 2/98/1 | 3/75/0 | 0/4/0 |
A. A summary of clinical parameters for the 430 IDC tumors of TCGA cohort for each histological grade. B. A summary of clinical parameters for the 183 IDC tumors of TCGA cohort for each subclass. ER: estrogen receptor. PGR: progesterone receptor. HER2: human epidermal growth factor receptor 2. LN: Lymph node. M: Metastasis. NA: not available. eq: equivocal. SD: standard deviation. ER, PgR and Her2 status were determined using Immunohistochemistry (IHC). Tumor stages determined according to American Joint Committee on Cancer system (AJCC). Histological grades were estimated using Nottingham Histologic Score, Scarff-Bloom-Richardson grading system (SBR), or Elston grading method.